Deutsche Bank’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-659,115
| Closed | -$119M | – | 5337 |
|
|
2017
Q3 | $119M | Buy |
659,115
+451,378
| +217% | +$62.9M | 0.08% | 283 |
|
|
2017
Q2 | $21.5M | Buy |
207,737
+11,875
| +6% | +$969K | 0.02% | 907 |
|
|
2017
Q1 | $15.4M | Buy |
195,862
+9,323
| +5% | +$576K | 0.01% | 1016 |
|
|
2016
Q4 | $8.36M | Sell |
186,539
-23,310
| -11% | -$1.14M | 0.01% | 1377 |
|
|
2016
Q3 | $11.7M | Buy |
209,849
+73,756
| +54% | +$4.11M | 0.01% | 1210 |
|
|
2016
Q2 | $6.8M | Buy |
136,093
+108,617
| +395% | +$5.34M | ﹤0.01% | 1543 |
|
|
2016
Q1 | $1.26M | Sell |
27,476
-93,398
| -77% | -$4.52M | ﹤0.01% | 2668 |
|
|
2015
Q4 | $7.45M | Buy |
120,874
+110,409
| +1,055% | +$7.77M | 0.01% | 1520 |
|
|
2015
Q3 | $581K | Buy |
10,465
+1,342
| +15% | +$84.4K | ﹤0.01% | 3283 |
|
|
2015
Q2 | $555K | Sell |
9,123
-2,577
| -22% | -$147K | ﹤0.01% | 3339 |
|
|
2015
Q1 | $673K | Buy |
11,700
+2,792
| +31% | +$187K | ﹤0.01% | 3141 |
|
|
2014
Q4 | $513K | Buy |
8,908
+8,905
| +296,833% | +$375K | ﹤0.01% | 3651 |
|
|
2014
Q3 | $0 | Buy |
+3
| New | +$74 | ﹤0.01% | 6242 |
|
Deutsche Bank's KITE Position: Q4 2017 in Review
Deutsche Bank sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 659,115 shares — an estimated $119M sold.
Deutsche Bank first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $119M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Deutsche Bank reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Deutsche Bank sold 659,115 Kite Pharma, Inc. shares in Q4 2017, an estimated $119M.
- Deutsche Bank first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
- Deutsche Bank's Kite Pharma, Inc. position peaked at $119M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Deutsche Bank's 13F filing for Q4 2017, filed 14 Feb 2018.